Literature DB >> 22977603

Oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity in rabbits.

Renchun Lai1, Yuhui Long, Qiuli Li, Xu Zhang4, Tiehua Rong4.   

Abstract

This study was performed to determine whether oxidative stress markers may be early markers of doxorubicin-induced cardiotoxicity. Forty-four male rabbits were randomly divided into four doxorubicin groups and one control group (8 rabbits). The control group received saline, and rabbits in the doxorubicin groups received 2 mg/kg doxorubicin weekly for 1 (group 1, 8 rabbits), 2 (group 2, 8 rabbits), 4 (group 3, 9 rabbits) or 8 (group 4, 11 rabbits) weeks. Echocardiography was performed to measure left ventricular ejection fraction, fractional shortening and the E/A ratio. Cardiotoxicity scores were determined by light microscopy using Billingham's method and by electron microscopy. Serum glutathione peroxidase (GPx) and superoxide dismutase (SOD) concentrations were quantified by a rabbit-specific enzyme-linked immunosorbent assay (ELISA). The Billingham cardiomyopathy scores for the rabbits in groups 3 or 4 were significantly higher (p<0.05) compared to the scores for the control group or groups 1 and 2. Myocardial injury was demonstrable by electron microscopy in groups 2, 3 and 4 (p<0.05). Serum GPx concentrations decreased only in group 4 compared to the control group (p<0.05). No changes were measured in serum SOD concentration. The results indicate that oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity.

Entities:  

Year:  2011        PMID: 22977603      PMCID: PMC3440815          DOI: 10.3892/etm.2011.306

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  18 in total

Review 1.  Long-term effects of treatments for childhood cancers.

Authors:  Jorge A Alvarez; Rebecca E Scully; Tracie L Miller; F Daniel Armstrong; Louis S Constine; Debra L Friedman; Steven E Lipshultz
Journal:  Curr Opin Pediatr       Date:  2007-02       Impact factor: 2.856

2.  Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma.

Authors:  E Kaya; L Keskin; I Aydogdu; I Kuku; N Bayraktar; M A Erkut
Journal:  J Int Med Res       Date:  2005 Nov-Dec       Impact factor: 1.671

3.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

Authors:  J P Krischer; S Epstein; D D Cuthbertson; A M Goorin; M L Epstein; S E Lipshultz
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

4.  Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.

Authors:  Rosalba Torrisi; Anna Cardillo; Giuseppe Cancello; Silvia Dellapasqua; Alessandra Balduzzi; Raffaella Ghisini; Alberto Luini; Paolo Veronesi; Giuseppe Viale; Aron Goldhirsch; Marco Colleoni
Journal:  Clin Breast Cancer       Date:  2010-12-01       Impact factor: 3.225

5.  The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia.

Authors:  J M Horacek; M Vasatova; M Tichy; R Pudil; L Jebavy; J Maly
Journal:  Exp Oncol       Date:  2010-07

6.  Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.

Authors:  Karen Li; Rita Yn Tz Sung; Wei Zhe Huang; Mo Yang; Nga Hin Pong; Shuk Man Lee; Wood Yee Chan; Hailu Zhao; Man Yin To; Tai Fai Fok; Chi Kong Li; Yuek Oi Wong; Pak Cheung Ng
Journal:  Circulation       Date:  2006-05-01       Impact factor: 29.690

7.  Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.

Authors:  Giuseppe Mercuro; Christian Cadeddu; Alessandra Piras; Mariele Dessì; Clelia Madeddu; Martino Deidda; Roberto Serpe; Elena Massa; Giovanni Mantovani
Journal:  Oncologist       Date:  2007-09

8.  Anthracycline cardiomyopathy monitored by morphologic changes.

Authors:  M E Billingham; J W Mason; M R Bristow; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

9.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

10.  Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study.

Authors:  M Faber; C Coudray; H Hida; M Mousseau; A Favier
Journal:  Biol Trace Elem Res       Date:  1995 Jan-Mar       Impact factor: 3.738

View more
  2 in total

1.  Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells.

Authors:  Tareck Rharass; Adam Gbankoto; Christophe Canal; Gizem Kurşunluoğlu; Amandine Bijoux; Daniela Panáková; Anne-Cécile Ribou
Journal:  Mol Cell Biochem       Date:  2016-01-30       Impact factor: 3.396

2.  Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity.

Authors:  Li Tang; Rui Duan; Yan-jun Zhong; Raymond A Firestone; Ya-ping Hong; Ji-guo Li; Yan-chao Xin; Han-lin Wu; Yan Li
Journal:  Mol Cancer       Date:  2014-03-03       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.